 |
市場調查報告書
商品編碼
2038975
暴食症治療市場：依治療方法、給藥途徑、通路及地區分類Bulimia Nervosa Treatment Market, By Treatment Type, By Route of Administration, By Distribution Channel, By Geography |
||||||
價格
簡介目錄
據估計，2026年神經性貪食症治療市場規模為6.448億美元，預計2033年將達到9.646億美元。預計從2026年到2033年，該市場將以5.2%的複合年成長率成長。
| 報告範圍 | 報告詳情 | ||
|---|---|---|---|
| 基準年： | 2025 | 2026年市場規模： | 6.448億美元 |
| 歷史數據時期： | 2020-2024 | 預測期： | 2026-2033 |
| 2026年至2033年預測期間的複合年成長率： | 5.20% | 2033年市場規模預測： | 9.646億美元 |
神經性貪食症（心因性暴食症）是一種飲食障礙，其特徵是在短時間內攝取大量食物，之後患者往往會嘗試透過兩種方式減肥：「排放」和非排放。排放包括餐後嘔吐，而非排放則包括禁食、灌腸、使用瀉藥和利尿劑、過度運動。心因性暴食症可導致多種危及生命的併發症，包括齲齒和牙齦疾病、心臟問題、自殘、脫水和消化器官系統問題。
市場動態
研究機構正致力於推出網站，以提高大眾對最新飲食障礙治療方法的認知度，預計這將推動預測期內的市場成長。例如，2018年，非營利組織ECRI Labs推出了一個面向患者及其看護者的貪食症指南網站。該網站提供貪食症治療方法的指導原則和最新資訊。
研究機構正在進行臨床試驗，以檢驗行為療法在治療飲食障礙的有效性。例如，2020年11月7日，美國國家心理健康實驗室（NIMH）宣布，正在招募患有神經性貪食症的成年女性患者參與一項臨床試驗，以確認認知行為療法在治療神經性貪食症方面的有效性。
本研究的關鍵特徵
- 本研究揭示了各個細分市場的潛在商機，並說明了該市場極具吸引力的投資提案矩陣。
- 此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和核准、區域前景以及領先企業採取的競爭策略。
- 本研究根據以下參數對全球神經性貪食症治療市場的主要參與者進行了分析：公司概況、財務業績、產品系列、地理企業發展、分銷策略、關鍵發展和策略以及未來計劃。
- 透過利用本報告中的見解，企業行銷負責人和經營團隊將能夠就未來的產品發布、技術升級、市場擴張和行銷策略做出明智的決策。
- 這份「全球貪食症治療市場報告」旨在為該行業的各種相關人員提供服務，包括投資者、供應商、製造商、經銷商、新參與企業和金融分析師。
- 相關人員可以透過在暴食症治療市場分析中使用的各種策略矩陣輕鬆做出決策。
目錄
第1章：研究目標與前提條件
- 研究目標
- 前提
- 簡稱
第2章 市場概覽
- 報告摘要
- 市場定義和範圍
- 執行摘要
- 一致性機會圖（COM）
第3章：市場動態、監管與趨勢分析
- 市場動態
- 促進因素
- 抑制因子
- 市場機遇
- 影響分析
- 流行病學
- 法規環境
- PEST分析
- 產品發布
- 併購趨勢
第4章 全球神經性貪食症治療市場：依治療方法，2021-2033年
- 藥物治療
- 非藥物治療
第5章 全球神經性貪食症治療市場：依給藥途徑分類，2021-2033年
- 口服
- 靜脈
- 其他
第6章 全球神經性貪食症治療市場：依通路分類，2021-2033年
- 醫院藥房
- 零售藥房
- 網路藥房
第7章 全球神經性貪食症治療市場：依地區分類，2021-2033年
- 北美洲
- 美國
- 加拿大
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲
- 歐洲
- 德國
- 英國
- 法國
- 義大利
- 西班牙
- 俄羅斯
- 其他歐洲國家
- 亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 其他亞太地區
- 中東
- GCC
- 以色列
- 其他中東國家
- 非洲
- 南非
- 中非
- 北非
第8章 競爭情勢
- 公司簡介
- Allergan, Inc.
- Eli Lilly and Company
- AstraZeneca plc
- Alembic Pharmaceuticals Ltd
- Bristol-Myers Squibb Company
- GlaxoSmithKline plc
- Pfizer Inc.
- Johnson & Johnson Services, Inc.
- Reddy's Laboratories Limited
- Lupin Pharmaceuticals, Inc.
- Aurobindo Pharma
- Zydus Cadila
- Apotex Inc.
- Teva Pharmaceutical Industries Ltd
- Sun Pharmaceutical Industries Ltd
第9章
- 參考
- 調查方法
簡介目錄
Product Code: CMI4323
Bulimia Nervosa Treatment Market is estimated to be valued at USD 644.8 Mn in 2026 and is expected to reach USD 964.6 Mn by 2033, growing at a compound annual growth rate (CAGR) of 5.2% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 644.8 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 5.20% | 2033 Value Projection: | USD 964.6 Mn |
Bulimia nervosa is a type of eating disorder, in which the person eat large amount of food (binge eating) within a short period of time, after which the person tends to lose weight by two ways: purging and non-purging. Purging includes vomiting post eating and non-purging includes fasting, enemas, use of laxatives and diuretics, and excessive exercising. Bulimia nervosa may lead to various life-threatening complications such as tooth & gum decay, heart problems, self-injury, dehydration, and digestive problems.
Market Dynamics
Research institutes are indulged in launching websites, in order to spread awareness about the latest eating disorders treatment options, among the population, which is expected to fuel growth of the market over the forecast period. For instance, in 2018, ECRI institute, a non-profit organization, launched a bulimia nervosa guide website for the patients and their caretakers. This website provide guidelines and latest information about the treatment options for the bulimia nervosa.
Research institutes are indulged in conducting clinical trials for finding the effectiveness of behavioral therapy for the treatment of eating disorders. For instance, on 7th November 2020, National Institute of Mental Health (NIMH) announced that, they are recruiting adult women patients suffering from bulimia nervosa for conducting clinical trials, in order to determine the effectiveness of cognitive behavioral therapy in the treatment of bulimia nervosa.
Key features of the study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
- It profiles leading players in the global bulimia nervosa treatment market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
- Key companies covered as a part of this study include Allergan, Inc., Eli Lilly and Company, AstraZeneca plc, Alembic Pharmaceuticals Ltd, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Pfizer Inc., Johnson & Johnson Services, Inc., Dr. Reddy's Laboratories Limited, Lupin Pharmaceuticals, Inc., Aurobindo Pharma, Zydus Cadila, Apotex Inc., Teva Pharmaceutical Industries Ltd, and Sun Pharmaceutical Industries Ltd.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
- The global bulimia nervosa treatment market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision making through various strategy matrices used in analyzing the bulimia nervosa treatment market
Market Segmentation
- By Treatment Type (Revenue, USD Mn, 2021-2033)
- Drug Treatment
- Selective Serotonin Reuptake Inhibitor (SSRI)
- Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
- Benzodiazepines
- Tricyclic Antidepressants
- Others
- Non-drug Treatment
- Nutritional Therapy
- Behavioral Therapy
- Others
- By Route of Administration (Revenue, USD Mn, 2021-2033)
- Oral
- Intravenous
- Others
- By Distribution Channel (Revenue, USD Mn, 2021-2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Bulimia Nervosa Treatment Market, By Region: (Revenue, USD Mn, 2021-2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Key Players
- Allergan, Inc.
- Eli Lilly and Company
- AstraZeneca plc
- Alembic Pharmaceuticals Ltd
- Bristol-Myers Squibb Company
- GlaxoSmithKline plc
- Pfizer Inc.
- Johnson & Johnson Services, Inc.
- Reddy's Laboratories Limited
- Lupin Pharmaceuticals, Inc.
- Aurobindo Pharma
- Zydus Cadila
- Apotex Inc.
- Teva Pharmaceutical Industries Ltd
- Sun Pharmaceutical Industries Ltd
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Treatment Type
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Epidemiology
- Key Developments
- Regulatory Scenario
- PEST Analysis
- Product launches
- Acquisition and Merger Scenario
4. Global Bulimia Nervosa Treatment Market, By Treatment Type, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026, and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Drug Treatment
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Selective Serotonin Reuptake Inhibitor (SSRI)
- Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
- Benzodiazepines
- Tricyclic Antidepressants
- Others
- Non-drug Treatment
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Nutritional Therapy
- Behavioral Therapy
- Others
5. Global Bulimia Nervosa Treatment Market, By Route of Administration, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026, and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Oral
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Intravenous
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Others
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
6. Global Bulimia Nervosa Treatment Market, By Distribution Channel, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026, and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacies
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Retail Pharmacies
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Online Pharmacies
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
7. Global Bulimia Nervosa Treatment Market, By Region, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, By Region, 2026, and 2033 (%)
- Y-o-Y Growth Analysis, For Region, 2022 - 2033
- North America
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Treatment Type, 2021- 2033, (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021- 2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021- 2033, (USD Mn)
- Market Size and Forecast, By Country, 2021- 2033, (USD Mn)
- U.S.
- Canada
- Latin America
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Treatment Type, 2021- 2033, (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021- 2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021- 2033, (USD Mn)
- Market Size and Forecast, By Country, 2021- 2033, (USD Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Treatment Type, 2021- 2033, (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021- 2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021- 2033, (USD Mn)
- Market Size and Forecast, By Country, 2021- 2033, (USD Mn)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Treatment Type, 2021- 2033, (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021- 2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021- 2033, (USD Mn)
- Market Size and Forecast, By Country, 2021- 2033, (USD Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Treatment Type, 2021- 2033, (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021- 2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021- 2033, (USD Mn)
- Market Size and Forecast, By Country, 2021- 2033, (USD Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Treatment Type, 2021- 2033, (USD Mn)
- Market Size and Forecast, By Route of Administration, 2021- 2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2021- 2033, (USD Mn)
- Market Size and Forecast, By Country, 2021- 2033, (USD Mn)
- South Africa
- Central Africa
- North Africa
8. Competitive Landscape
- Company Profiles
- Allergan, Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Eli Lilly and Company
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- AstraZeneca plc
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Alembic Pharmaceuticals Ltd
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Bristol-Myers Squibb Company
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- GlaxoSmithKline plc
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Pfizer Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Johnson & Johnson Services, Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Reddy's Laboratories Limited
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Lupin Pharmaceuticals, Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Aurobindo Pharma
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Zydus Cadila
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Apotex Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Teva Pharmaceutical Industries Ltd
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Sun Pharmaceutical Industries Ltd
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Analyst Views
- Allergan, Inc.
9. Section
- References
- Research Methodology
- About us and Sales Contact
02-2729-4219
+886-2-2729-4219
神經性貪食症市場：依治療類型、治療環境、通路和最終用戶分類－2026-2032年全球市場預測
貪食症治療市場－全球產業規模、佔有率、趨勢、機會、預測：按類型、通路、地區和競爭格局分類，2021-2031年